Conditions: Renal Transplantation
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 14
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the pharmacokinetics and safety of belatacept in de novo renal transplant subjects treated with belatacept-based immunosuppressant medication

Detailed description:

Arms:
arm 1: 10mg/kg

6 doses (Day 1, 5, week 2, 4, 8 and 12) for 12 weeks arm 2: 5mg/kg

33 doses (every 4 weeks) for 144 weeks

Interventions: intervention 1: Belatacept
Intervention descriptions: intervention 1: IV infusion

Protocol document: